Promising drug cocktail targets rare thymus cancers before surgery

NCT ID NCT01025089

First seen Jan 11, 2026 · Last updated Apr 28, 2026 · Updated 13 times

Summary

This study tested whether adding the targeted drug cetuximab to standard chemotherapy could shrink advanced thymoma or thymic carcinoma tumors before surgery. 18 adults with stage II to IVA disease received the combination, then had their tumors removed. Researchers measured how many patients had no cancer cells left in the surgical specimen and tracked side effects and genetic markers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYMOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010-3000, United States

  • Md Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center

    Sleepy Hollow, New York, 10591, United States

  • Memorial Sloan Kettering West Harrison

    Harrison, New York, 10604, United States

  • Memorial Sloan Kettering at Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering at Mercy Medical Center

    Rockville Centre, New York, United States

Conditions

Explore the condition pages connected to this study.